Premium
Plasma microRNAs as biomarkers of pancreatic cancer risk in a prospective cohort study
Author(s) -
Duell Eric J.,
LujanBarroso Leila,
Sala Núria,
Deitz McElyea Samantha,
Overvad Kim,
Tjonneland Anne,
Olsen Anja,
Weiderpass Elisabete,
Busund LillTove,
Moi Line,
Muller David,
Vineis Paolo,
Aune Dagfinn,
Matullo Giuseppe,
Naccarati Alessio,
Panico Salvatore,
Tagliabue Giovanna,
Tumino Rosario,
Palli Domenico,
Kaaks Rudolf,
Katzke Verena A.,
Boeing Heiner,
BuenodeMesquita H. Bas,
Peeters Petra H.,
Trichopoulou Antonia,
Lagiou Pagona,
Kotanidou Anastasia,
Travis Ruth C.,
Wareham Nick,
Khaw KayTee,
Ramon Quiros Jose,
RodríguezBarranco Miguel,
Dorronsoro Miren,
Chirlaque MaríaDolores,
Ardanaz Eva,
Severi Gianluca,
BoutronRuault MarieChristine,
Rebours Vinciane,
Brennan Paul,
Gunter Marc,
Scelo Ghislaine,
Cote Greg,
Sherman Stuart,
Korc Murray
Publication year - 2017
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.30790
Subject(s) - medicine , prospective cohort study , logistic regression , pancreatic cancer , cohort , case control study , oncology , cohort study , cancer , biomarker , receiver operating characteristic , area under the curve , biology , biochemistry
Noninvasive biomarkers for early pancreatic ductal adenocarcinoma (PDAC) diagnosis and disease risk stratification are greatly needed. We conducted a nested case‐control study within the Prospective Investigation into Cancer and Nutrition (EPIC) cohort to evaluate prediagnostic microRNAs (miRs) as biomarkers of subsequent PDAC risk. A panel of eight miRs (miR‐10a, ‐10b, ‐21‐3p, ‐21‐5p, ‐30c, ‐106b, ‐155 and ‐212) based on previous evidence from our group was evaluated in 225 microscopically confirmed PDAC cases and 225 controls matched on center, sex, fasting status and age/date/time of blood collection. MiR levels in prediagnostic plasma samples were determined by quantitative RT‐PCR. Logistic regression was used to model levels and PDAC risk, adjusting for covariates and to estimate area under the receiver operating characteristic curves (AUC). Plasma miR‐10b, ‐21‐5p, ‐30c and ‐106b levels were significantly higher in cases diagnosed within 2 years of blood collection compared to matched controls (all p ‐values <0.04). Based on adjusted logistic regression models, levels for six miRs (miR‐10a, ‐10b, ‐21‐5p, ‐30c, ‐155 and ‐212) overall, and for four miRs (‐10a, ‐10b, ‐21‐5p and ‐30c) at shorter follow‐up time between blood collection and diagnosis (≤5 yr, ≤2 yr), were statistically significantly associated with risk. A score based on the panel showed a linear dose‐response trend with risk ( p ‐value = 0.0006). For shorter follow‐up (≤5 yr), AUC for the score was 0.73, and for individual miRs ranged from 0.73 (miR‐212) to 0.79 (miR‐21‐5p).